Genentech’s Subcutaneous Tecentriq Shows Non-Inferiority To I.V. Formulation

 
• By Joseph Haas
SubQ
Genentech plans to seek approval of a subcutaneous version of Tecentriq • Source: Shutterstock

More from Clinical Trials

More from R&D